BioMendics, LLC® is dedicated to the treatment of rare genetic skin disorders, acute wounds, burns, antibiotics and inflammatory skin conditions. The company’s lead product in development, TolaSure™, is a patented topical gel containing small-molecule liquid crystals that help promote all phases of the healing process and interact with the skins naturally occurring electrical currents of injury for enhanced proliferation and directed cell migration.

BioMendics is currently planning a Phase I/IIa clinical trial for epidermolysis bullosa simplex (EBS) patients as a result of successful preclinical studies and a strong safety profile in both the Phase I and II clinical studies in acute wound trials.

Industry Sector
Biomedical & Health Tech

Founded
2014

JumpStart Investment
Focus Fund